Nuveen
ELVN icon

Nuveen’s Enliven Therapeutics ELVN Stock Holding History

Nuveen’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Buy
374,217
+268,334
+253% +$11.4M ﹤0.01% 1295
2026
Q1 		$4.15M Buy
105,883
+435
+0.4% +$12.1K ﹤0.01% 1960
2025
Q4 		$1.62M Sell
105,448
-2,796
-3% -$55.7K ﹤0.01% 2377
2025
Q3 		$2.22M Buy
108,244
+18,532
+21% +$374K ﹤0.01% 2265
2025
Q2 		$1.8M Sell
89,712
-14,387
-14% -$272K ﹤0.01% 2353
2025
Q1 		$2.05M Buy
104,099
+73
+0.1% +$1.57K ﹤0.01% 2329
2024
Q4 		$2.34M Buy
104,026
+317
+0.3% +$8.22K ﹤0.01% 2318
2024
Q3 		$2.65M Sell
103,709
-23,809
-19% -$551K ﹤0.01% 2283
2024
Q2 		$2.98M Buy
127,518
+44,523
+54% +$937K ﹤0.01% 2189
2024
Q1 		$1.46M Sell
82,995
-3,634
-4% -$55.8K ﹤0.01% 2535
2023
Q4 		$1.2M Sell
86,629
-338
-0.4% -$4.13K ﹤0.01% 2654
2023
Q3 		$1.19M Buy
86,967
+22,272
+34% +$375K ﹤0.01% 2509
2023
Q2 		$1.32M Buy
+64,695
New +$1.31M ﹤0.01% 2530
2021
Q2 		– Sell
-3,728
Closed -$126K – 3413
2021
Q1 		$126K Buy
+3,728
New +$189K ﹤0.01% 3270
2020
Q3 		– Sell
-1,989
Closed -$220K – 3309
2020
Q2 		$220K Buy
+1,989
New +$223K ﹤0.01% 3087

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Nuveen's ELVN Position: Q2 2026 in Review

Nuveen increased its Enliven Therapeutics (ELVN) stake by 253% in Q2 2026, buying an estimated $11.4M and bringing the position to 374,217 shares worth $19M. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

Nuveen first reported a position in ELVN in Q2 2020 and has held it in 15 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Nuveen held 374,217 shares of Enliven Therapeutics worth $19M as of Q2 2026.
  • Nuveen bought 268,334 Enliven Therapeutics shares in Q2 2026, an estimated $11.4M.
  • Enliven Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1295 holding.
  • Nuveen first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 15 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.